BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson DB, Jakubovic BD, Sibaud V, Sise ME. Balancing Cancer Immunotherapy Efficacy and Toxicity. J Allergy Clin Immunol Pract 2020;8:2898-906. [PMID: 32599218 DOI: 10.1016/j.jaip.2020.06.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Blumenthal KG, Phillips EJ. Positioning Drug Allergy Delabeling as a Critical Tool for Precision Medicine, Quality Improvement, and Public Health. J Allergy Clin Immunol Pract 2020;8:2916-9. [PMID: 32781047 DOI: 10.1016/j.jaip.2020.07.046] [Reference Citation Analysis]
2 Deng C, Yang M, Jiang H, Wang R, Yang Z, Sun H, Cui H. Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report. Front Oncol 2021;11:664809. [PMID: 34540659 DOI: 10.3389/fonc.2021.664809] [Reference Citation Analysis]
3 Gavali S, Liu J, Li X, Paolino M. Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy. Int J Mol Sci 2021;22:10800. [PMID: 34639141 DOI: 10.3390/ijms221910800] [Reference Citation Analysis]
4 Anderson G. Tumour Microenvironment: Roles of the Aryl Hydrocarbon Receptor, O-GlcNAcylation, Acetyl-CoA and Melatonergic Pathway in Regulating Dynamic Metabolic Interactions across Cell Types-Tumour Microenvironment and Metabolism. Int J Mol Sci 2020;22:E141. [PMID: 33375613 DOI: 10.3390/ijms22010141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Adorisio S, Cannarile L, Delfino DV, Ayroldi E. Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? Cells 2021;10:2333. [PMID: 34571982 DOI: 10.3390/cells10092333] [Reference Citation Analysis]
6 Fujisaki T, Watanabe S, Ota T, Kushiro K, Sato Y, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Matsumoto N, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events. Front Oncol 2021;11:704475. [PMID: 34631533 DOI: 10.3389/fonc.2021.704475] [Reference Citation Analysis]
7 Lee MD, Seethapathy H, Strohbehn IA, Zhao SH, Boland GM, Fadden R, Sullivan R, Reynolds KL, Sise ME. Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. J Immunother Cancer 2021;9:e002292. [PMID: 33849926 DOI: 10.1136/jitc-2020-002292] [Reference Citation Analysis]
8 Wu X, Bai Z. Multi-omics analysis of m6A modification-related patterns based on m6A regulators and tumor microenvironment infiltration in lung adenocarcinoma. Sci Rep 2021;11:20921. [PMID: 34686691 DOI: 10.1038/s41598-021-00272-z] [Reference Citation Analysis]
9 Peng L, Liang WH, Mu DG, Xu S, Hong SD, Stebbing J, Liang F, Xia Y. First-Line Treatment Options for PD-L1-Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Front Oncol 2021;11:657545. [PMID: 34249693 DOI: 10.3389/fonc.2021.657545] [Reference Citation Analysis]